Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

Key facts

Sponsor

Mesoblast International Sàrl

Principal Investigator

Elizabeth Burke, ANP-C

Mesoblast, Inc.

Intervention

Remestemcel-L(drug)

Eligibility

18 years · All sexes

Study locations (1)

• Mount Sinai Hospital, New York, New York, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06990477
  Effect of EIT-guided PEEP in ARDS Patients With Higher Recruitability
  Southeast University, China
• RECRUITINGNANCT07362537
  Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS
  Southeast University, China
• RECRUITINGNCT07284888
  Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry-Based Observational Study
  Southeast University, China
• RECRUITINGPHASE3NCT06994442
  Optimizing Pain Treatment in Children On Mechanical Ventilation
  Weill Medical College of Cornell University
• RECRUITINGNANCT07326215
  A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
  Vantive Health LLC
• RECRUITINGNCT07269743
  AEROSOL THERAPY IN ARDS PATIENTS (AERO-IN-ARDS)
  TS Misra Medical College
• RECRUITINGNCT06919484
  The Physiological Effect of RCexp on Ventilation/Perfusion Distribution
  Southeast University, China
• RECRUITINGNCT07090460
  Pulmonary Overdistension Assessment With Electrical Impedance Tomography in Patients With Acute Respiratory Distress Syndrom in Prone Position.
  Centre Hospitalier de la côte Basque

See all trials for Adult acute respiratory distress syndrome →